Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Total Non-Current Liabilities (2018 - 2020)

CNBX Pharmaceuticals (CNBX) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $232627.0 as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Total Non-Current Liabilities rose 109.98% year-over-year to $232627.0, compared with a TTM value of $232627.0 through May 2020, up 109.98%, and an annual FY2019 reading of -$2.3 million, down 621.62% over the prior year.
  • Total Non-Current Liabilities was $232627.0 for Q2 2020 at CNBX Pharmaceuticals, up from -$2.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $449660.0 in Q3 2018 and bottomed at -$2.4 million in Q1 2019.
  • Average Total Non-Current Liabilities over 3 years is -$1.7 million, with a median of -$2.3 million recorded in 2019.
  • The sharpest move saw Total Non-Current Liabilities crashed 621.62% in 2019, then surged 109.98% in 2020.
  • Year by year, Total Non-Current Liabilities stood at -$2.4 million in 2018, then decreased by 0.52% to -$2.4 million in 2019, then skyrocketed by 109.76% to $232627.0 in 2020.
  • Business Quant data shows Total Non-Current Liabilities for CNBX at $232627.0 in Q2 2020, -$2.3 million in Q1 2020, and -$2.4 million in Q4 2019.